Kybella injections might be the solution for you. Kybella is the first and only FDA-approved injectable treatment to improve the appearance of moderate to severe fat beneath the chin and it is now offered here at The Beauty Medics.
Double chins can be caused by many factors including aging, weight gain, or genetics. In the past, it was impossible to improve your chin profile with diet or exercise, meaning you had to resort to surgery or live with a double chin. Now, Kybella offers a quick and minimally invasive way to reduce chin fat.
Kybella works by destroying the fat cells when injected into the fat beneath the chin. Once the cells are destroyed, they naturally leave the body, improving your chin profile. The active ingredient in Kybella is deoxycholic acid, a naturally occurring molecule in the body that aids in the breakdown of dietary fat. Treatments take only about 15 minutes, and you can resume your normal routine immediately, with few visible side effects.
Here at The Beauty Medics, we can assure you that you will receive the only FDA-approved injectable treatment. We can administer Kybella during your office visit and will make sure you feel comfortable and at ease. Contact us today to schedule a consult!
KYBELLA® (deoxycholic acid) injection 10 mg/mL Important Information
KYBELLA® (deoxycholic acid) injection is indicated for improvement in the appearance of moderate to severe convexity or fullness associated with submental fat in adults.
The safe and effective use of KYBELLA® for the treatment of subcutaneous fat outside the submental region has not been established and is not recommended.
KYBELLA® is contraindicated in the presence of infection at the injection sites.
Marginal Mandibular Nerve Injury
Cases of marginal mandibular nerve injury, manifested as an asymmetric smile or facial muscle weakness, were reported in 4% of subjects in the clinical trials; all cases resolved spontaneously (range 1-298 days, median 44 days). KYBELLA® should not be injected into or in close proximity to the marginal mandibular branch of the facial nerve.
Dysphagia occurred in 2% of subjects in the clinical trials in the setting of administration-site reactions, eg, pain, swelling, and induration of the submental area; all cases of dysphagia resolved spontaneously (range 1-81 days, median 3 days). Avoid use of KYBELLA® in patients with current or prior history of dysphagia as treatment may exacerbate the condition.
In clinical trials, 72% of subjects treated with KYBELLA® experienced hematoma/bruising. KYBELLA® should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet or anticoagulant therapy as excessive bleeding or bruising in the treatment area may occur.
Risk of Injecting Into or in Proximity to Vulnerable Anatomic Structures
To avoid the potential of tissue damage, KYBELLA® should not be injected into or in close proximity (1 cm-1.5 cm) to salivary glands, lymph nodes, and muscles.
The most commonly reported adverse reactions in the pivotal clinical trials were: injection site edema/swelling, hematoma/bruising, pain, numbness, erythema, and induration.
• Contact •
• Hours •
Monday through Saturday
9:00AM – 6:00PM
• Location •
4646 Brockton Ave #301
Riverside, CA 92506